Abstract
Glioblastomas are the most aggressive of all gliomas and have the worst prognosis, with 5-year survival rates of less than 10%. Temozolomide (TMZ) is a DNA-methylating agent. Now that TMZ is available, the standard treatment is maximal safe resection, followed by treatment with radiation and TMZ. TMZ has also been used for maintenance therapy. Recently, bevacizumab, which is a monoclonal antibody to vascular endothelial growth factor, has been used for the initial treatment of glioblastomas and for the treatment of recurrent glioblastomas. A 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) wafer can also be placed on the surface of the cavity after near-complete tumor resection. These are currently the three drugs that are most often used to treat glioblastomas. In the near future, other therapeutic options such as immunotherapy may be used to treat glioblastomas.
Keywords: Antiepileptic drug, BCNU wafer, bevacizumab, glioblastoma, PD-1, radiotherapy, temozolomide.
Current Medicinal Chemistry
Title:Current and Future Drug Treatments for Glioblastomas
Volume: 23 Issue: 38
Author(s): Shigeo Ohba and Yuichi Hirose
Affiliation:
Keywords: Antiepileptic drug, BCNU wafer, bevacizumab, glioblastoma, PD-1, radiotherapy, temozolomide.
Abstract: Glioblastomas are the most aggressive of all gliomas and have the worst prognosis, with 5-year survival rates of less than 10%. Temozolomide (TMZ) is a DNA-methylating agent. Now that TMZ is available, the standard treatment is maximal safe resection, followed by treatment with radiation and TMZ. TMZ has also been used for maintenance therapy. Recently, bevacizumab, which is a monoclonal antibody to vascular endothelial growth factor, has been used for the initial treatment of glioblastomas and for the treatment of recurrent glioblastomas. A 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) wafer can also be placed on the surface of the cavity after near-complete tumor resection. These are currently the three drugs that are most often used to treat glioblastomas. In the near future, other therapeutic options such as immunotherapy may be used to treat glioblastomas.
Export Options
About this article
Cite this article as:
Ohba Shigeo and Hirose Yuichi, Current and Future Drug Treatments for Glioblastomas, Current Medicinal Chemistry 2016; 23 (38) . https://dx.doi.org/10.2174/0929867323666161014132907
DOI https://dx.doi.org/10.2174/0929867323666161014132907 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in the Development of Selective Ligands for the Cannabinoid CB2 Receptor
Current Topics in Medicinal Chemistry Recent Advances in Copper Radiopharmaceuticals
Current Radiopharmaceuticals Approaching the Increasing Complexity of Non-small Cell Lung Cancer Taxonomy
Current Pharmaceutical Design Cannabinoid Drugs and Enhancement of Endocannabinoid Responses: Strategies for a Wide Array of Disease States
Current Molecular Medicine Novel Homeodomain Transcription Factor Nkx2.2 in the Brain Tumor Development
Current Cancer Drug Targets Pyrimidine Nucleosides in Molecular PET Imaging of Tumor Proliferation
Current Medicinal Chemistry Anti-Angiogenic Approaches to Malignant Gliomas
Current Cancer Drug Targets “Letting the Air In” Can Set the Stage for Tumor Recurrences
Current Cancer Therapy Reviews RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review)
Anti-Cancer Agents in Medicinal Chemistry Neuropilin and Neuropilin Associated Molecules as New Molecular Targets in Pancreatic Adenocarcinoma
Anti-Cancer Agents in Medicinal Chemistry Recent Patents, Formulation and Characterization of Nanoliposomes
Recent Patents on Drug Delivery & Formulation The Role of 3D Pharmacophore Mapping Based Virtual Screening for Identification of Novel Anticancer Agents: An Overview
Current Topics in Medicinal Chemistry Peptidergic Regulation of Pheochromocytoma
Current Pharmacogenomics Meet Our Editorial Board Member
Protein & Peptide Letters Post-Transcriptional and Post-translational Regulation of Central Carbon Metabolic Enzymes in Cancer
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Preliminary Evaluation of 5-[18F]fluoroleucine
Current Radiopharmaceuticals Interplay between Epigenetics & Cancer Metabolism
Current Pharmaceutical Design Targeting the Tumor Stroma in Cancer Therapy
Current Pharmaceutical Biotechnology Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design Oxazole-Based Compounds As Anticancer Agents
Current Medicinal Chemistry